BioSpace News Archive

Optibrium’s StarDrop™ drug discovery software inspires the next generation of high-school students in their challenge to target COVID-19

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain of SARS-CoV-2, the coronavirus that causes COVID-19.

Transgene and Hypertrust Patient Data Care announced as a world premiere the first productive blockchain solution for clinical trials of personalized healthcare, leveraging the Hypertrust X-Chain for Clinical Trials product.

Forbion, a leading European life sciences venture capital firm, announces the first close at EUR 185 million of its new Forbion Growth Opportunities Fund, focused on investing in late-stage European life sciences companies.

IRLAB announced that a scientific paper reporting the distinctive pharmacological profile of IRL752, in development for the treatment of impaired balance and falls in Parkinson’s disease, is accepted and published online in the Journal of Pharmacology and Experimental Therapeutics, JPET.

Subsidiary to Advance Commercial Development of Diagnostic Tests for Virology, COVID-19, Oncology

BIOASIS TECHNOLOGIES INC. (“Bioasis”) (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including rare genetic diseases,

Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, today announced it will report its financial results for the second quarter and six months ended June 30, 2020 after the stock market closes on Wednesday, Aug. 5, 2020.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on July 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 24,500 shares of Puma common stock to six new non-executive employees.

Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved the expanded use of Dysport® (abobotulinumtoxinA) in pediatric patients